Setback to Sun Pharma as Fibromun, Nidlegy Trials Miss Key Endpoints in Cancer Studies
New Delhi: Sun Pharmaceutical Industries Limited has shared clinical updates on Fibromun and Nidlegy, with key studies failing to meet primary endpoints while further trials and regulatory pathways continue to…